Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus BECLOMETHASONE DIPROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus BECLOMETHASONE DIPROPIONATE.
AZMACORT vs BECLOMETHASONE DIPROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Beclomethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through binding to glucocorticoid receptors, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory cytokines.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
Inhalation: 40-320 mcg twice daily (DPI or pMDI); maximum 640 mcg/day. Intranasal: 1-2 sprays (42-84 mcg) per nostril twice daily. Topical: Apply 0.025% cream/ointment twice daily.
None Documented
None Documented
Clinical Note
moderateBeclomethasone dipropionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Gatifloxacin."
Clinical Note
moderateBeclomethasone dipropionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rosoxacin."
Clinical Note
moderateBeclomethasone dipropionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Terminal elimination half-life is 2.8-3.1 hours after inhalation, with a slower phase attributed to slow dissolution from lung tissue; clinical context: supports twice-daily dosing.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Primarily fecal (via bile) as metabolites, ~60-70%; renal excretion accounts for <10% of unchanged drug.
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid
Beclomethasone dipropionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Trovafloxacin."